Lupin Board Okays Transfer Of API R&D Division To Arm

The company had on Feb. 12 intimated regarding the board's approval for the transfer of the OTC Consumer Healthcare Business to a new wholly owned subsidiary.

PTI

(Photo Source: Chokniti Khongchum/Pexels)

Drug firm Lupin Ltd. on Monday said its board has approved the transfer of its API R&D division to a wholly owned subsidiary on a slump sale basis.

The company's board has also approved modification to an earlier slump sale transaction by including an additional brand as part of the transfer of OTC business to LUPINLIFE Consumer Healthcare Ltd., on a going concern basis, the drug maker said in a regulatory filing.

The company had intimated on Feb. 12 this year regarding the board's approval for the transfer of the OTC Consumer Healthcare Business to a new wholly owned subsidiary.

The company has incorporated LUPINLIFE Consumer Healthcare, a wholly owned subsidiary for the purpose.

Also Read: Indian Pharma Could Gain Market Share Amid US Tariffs, Says JPMorgan

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit. Feel free to Add NDTV Profit as trusted source on Google.
GET REGULAR UPDATES
Add us to your Preferences
Set as your preferred source on Google
Google Badge